NCT00623142

Brief Summary

The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system during and after surgery. Furthermore, this study also aims to identify some of the post CABG clinical effects of HBO treatment prior to CABG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
81

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Jan 2005

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2007

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2008

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 14, 2008

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 25, 2008

Completed
Last Updated

July 15, 2019

Status Verified

July 1, 2019

Enrollment Period

2 years

First QC Date

February 14, 2008

Last Update Submit

July 11, 2019

Conditions

Keywords

Myocardial protectionIschemic Reperfusion InjuryHyperbaric OxygenPreconditioning

Outcome Measures

Primary Outcomes (7)

  • Myocardial Hsp72 protein

    Intra-operative (During CABG)

  • Myocardial eNOS protein

    Intra-Operative (During CABG)

  • Serum Troponin-T

    Peri-operative

  • Serum soluble ICAM-1

    Peri-operative

  • Serum soluble PSGL-1

    Peri-operative

  • Serum soluble P-Selectin

    Peri-operative

  • Serum soluble E-Selectin

    Peri-operative

Secondary Outcomes (14)

  • All cardiovascular haemodynamic parameters as measured by a pulmonary artery catheter

    Peri-operative

  • Duration of mechanical ventilation

    Post Operative

  • Duration of endotracheal intubation

    post operative

  • Length of stay in ICU

    Post-operative

  • Blood loss

    Post operative

  • +9 more secondary outcomes

Study Arms (2)

A

NO INTERVENTION

Patients in this arm were not treated with HBO prior to CABG

B

EXPERIMENTAL

Patients in this arm were treated with HBO prior to CABG

Drug: Hyperbaric Oxygen

Interventions

100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG

Also known as: Hyperbaric Oxygen Preconditioning
B

Eligibility Criteria

Age20 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective first time CABG
  • Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG

You may not qualify if:

  • Age ≤ 20 years or ≥ 85 years
  • Ejection fraction \< 30%
  • Unstable angina
  • Recent myocardial infarction (\< 1 month)
  • Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure)
  • Any end stage organ failure (e.g. renal and respiratory failure)
  • History of chronic obstructive pulmonary disease (COPD)
  • Pneumothorax
  • Pulmonary bullae
  • Convulsions
  • Current history of malignancy
  • Severe myopia or intraocular lens
  • Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hull & East Yorkshire NHS Trust (Castle Hill Hospital)

Hull, East Riding Of Yorkshire, HU16 5JQ, United Kingdom

Location

Related Publications (5)

  • Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Pharmacological preconditioning with hyperbaric oxygen: can this therapy attenuate myocardial ischemic reperfusion injury and induce myocardial protection via nitric oxide? J Surg Res. 2008 Sep;149(1):155-64. doi: 10.1016/j.jss.2007.09.003. Epub 2007 Oct 11.

    PMID: 17996900BACKGROUND
  • Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Can hyperbaric oxygen be used as adjunctive heart failure therapy through the induction of endogenous heat shock proteins? Adv Ther. 2007 Jan-Feb;24(1):106-18. doi: 10.1007/BF02849998.

    PMID: 17526467BACKGROUND
  • Yogaratnam JZ, Laden G, Madden LA, Seymour AM, Guvendik L, Cowen M, Greenman J, Cale A, Griffin S. Hyperbaric oxygen: a new drug in myocardial revascularization and protection? Cardiovasc Revasc Med. 2006 Jul-Sep;7(3):146-54. doi: 10.1016/j.carrev.2006.04.006.

    PMID: 16945821BACKGROUND
  • Jeysen ZY, Gerard L, Levant G, Cowen M, Cale A, Griffin S. Research report: the effects of hyperbaric oxygen preconditioning on myocardial biomarkers of cardioprotection in patients having coronary artery bypass graft surgery. Undersea Hyperb Med. 2011 May-Jun;38(3):175-85.

    PMID: 21721351BACKGROUND
  • Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Hyperbaric oxygen preconditioning improves myocardial function, reduces length of intensive care stay, and limits complications post coronary artery bypass graft surgery. Cardiovasc Revasc Med. 2010 Jan-Mar;11(1):8-19. doi: 10.1016/j.carrev.2009.03.004.

Related Links

MeSH Terms

Conditions

Myocardial Reperfusion Injury

Interventions

Hyperbaric Oxygenation

Condition Hierarchy (Ancestors)

CardiomyopathiesHeart DiseasesCardiovascular DiseasesMyocardial IschemiaVascular DiseasesReperfusion InjuryPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Oxygen Inhalation TherapyRespiratory TherapyTherapeutics

Study Officials

  • Jeysen Z Yogaratnam, MB.BCh, BAO, MRCS

    Hull & East Yorkshire NHS Trust (Castle Hill Hospital), United Kingdom

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

February 14, 2008

First Posted

February 25, 2008

Study Start

January 1, 2005

Primary Completion

January 1, 2007

Study Completion

January 1, 2008

Last Updated

July 15, 2019

Record last verified: 2019-07

Locations